Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Conditions
Interventions
Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome:Cell transfusion
Sponsors
The first affliated hospital of USTC (Anhui provincial hospital)
Eligibility
Sex/Gender
All
Age
14 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Multiple Myeloma: (1) Aged 18-80 years, race and gender not a concern; (2) Must be a high-risk patient and have received at least one treatment plan; (3) When collecting cells, patients do not receive systemic chemotherapy within 2 weeks (except lenalidomide, thalidomide or immunological checkpoint inhibitors such as CTLA4 and / or PD-1 / PD-L1 inhibitor) or not receiving radiotherapy within 3 weeks; (4) ECOG PS of 0 to 2; (5) hemoglobin > 80g / L (may be after transfusion); (6) Left ventricular ejection fraction (LVEF)=40%; (7) Expected survival time > 6 weeks; (8) serum creatinine = 1.6 mg / dl and / or urea nitrogen = 1.5 mg / dl; (9) serum AST and ALT = 5 times the normal value; (10) The patient has the ability to self-knowledge and can sign an informed consent form; 2. Lymphoma: (1) Hodgkin or non-Hodgkin's lymphoma patients with relapsed/refractory or at high risk of recurrence, or lymphomas with a second malignancy; (2) Aged 14-80 years old male and female; (3) When collecting cells, the patient does not receive systemic chemotherapy (including rituximab) within 2 weeks or not receiving radiotherapy within 3 weeks; (4) ECOG PS of 0 to 2; (5) Hemoglobin > 80g / L (may be after transfusion); (6) Left ventricular ejection fraction (LVEF)=40%; (7) Expected survival time > 6 weeks; (8) serum creatinine = 1.6 mg / dl and / or urea nitrogen = 1.5 mg / dl; (9) serum AST and ALT = 5 times the normal value; (10) The patient has the ability to self-knowledge and can sign an informed consent form; (11) The guardian of the child patient agrees to sign the informed consent form. 3. Acute Leukemia and MDS: (1) patients with relapsed/refractory or high risk of relapse (including acute lymphocytic leukemia, acute myeloid leukemia, acute mixed cell leukemia) or high-risk myelodysplastic syndrome; (2) Patients need to have indicators for testing or assessing disease when they are enrolled, including detection of minimal residual disease (MRD) using immunophenotyping, cytogenetics or PCR; (3) Aged 14-80 years old male and female; (4) When collecting cells, the patient does not receive systemic chemotherapy within 2 weeks or does not receive radiotherapy within 3 weeks; (5) ECOG PS of 0 to 2; (6) Hemoglobin > 80g / L (may be after transfusion); (7) Left ventricular ejection fraction (LVEF)=40%; (8) Expected survival time > 6 weeks; (9) Serum creatinine = 1.6 mg / dl and / or urea nitrogen = 1.5 mg / dl; (10) Serum AST and ALT = 5 times the normal value; (11) The patient has the ability to know and can sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Multiple myeloma: (1) pregnant or lactating women; (2) Patients with severe active infections; (3) Patients who require systemic glucocorticoids during cell collection or infusion due to their condition; (4) HIV-infected; (5) Absolute neutrophil counts caused by non-primary disease 15 seconds, PTT > 40 seconds, and / or INR > 1.5). 2. Lymphoma: 1)pregnant or lactating women; (2) Patients with severe active infections; (3) Patients who require systemic glucocorticoids during cell collection or infusion due to their condition; (4) HIV-infected ; (5) Absolute neutrophil counts caused by non-primary disease 15 seconds, PTT > 40 seconds, and / or INR > 1.5). 3. Acute Leukemia and MDS: (1) pregnant or lactating women; (2) Patients with severe active infections; (3) Patients who require systemic glucocorticoids during cell collection or infusion due to their condition; (4) Patients who have 2-4 degrees of acute or extensive chronic GVHD or treated with GVHD; (5) HIV-infected; (6) Platelet count caused by non-primary disease < 50,000 / µL; (7) When collecting cells, the patient received systemic chemotherapy or radiotherapy 1 week ago; (8) Absolute neutrophil counts caused by non-primary disease < 750 / microliter or platelet count < 50,000 / microliter; (9) Patients who received ATG or Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete response; | — |
Secondary
| Measure | Time frame |
|---|---|
| partial response; | — |
Contacts
Public ContactXingbing Wang
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Outcome results
None listed